CHRISTOPHER PLOWE

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Mechanisms of resistance of malaria parasites to antifolates
    Aric Gregson
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 Room 480, Baltimore, MD 21201, USA
    Pharmacol Rev 57:117-45. 2005
  2. pmc Pneumocystis pneumonia in HIV-positive adults, Malawi
    Joep J G van Oosterhout
    University of Malawi College of Medicine, Blantyre, Malawi
    Emerg Infect Dis 13:325-8. 2007
  3. pmc Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    PLoS ONE 3:e1465. 2008
  4. pmc Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial
    Matthew B Laurens
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e79323. 2013
  5. pmc Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    PLoS ONE 5:e9041. 2010
  6. pmc Prevalence and distribution of human Plasmodium infection in Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:297. 2013
  7. pmc A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:300. 2013
  8. pmc Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:310. 2013
  9. pmc Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali
    Drissa Coulibaly
    Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Point G, BP 1805, Bamako, Mali
    Malar J 12:82. 2013
  10. pmc Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment
    Ayesha M Shaukat
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 11:207. 2012

Research Grants

  1. DRUG RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 1999
  2. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2007
  3. Clinical trial of chloroquine combinations in Malawi
    CHRISTOPHER PLOWE; Fiscal Year: 2007
  4. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2003
  5. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2002
  6. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2002
  7. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2001
  8. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2001
  9. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2000

Detail Information

Publications66

  1. ncbi request reprint Mechanisms of resistance of malaria parasites to antifolates
    Aric Gregson
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 Room 480, Baltimore, MD 21201, USA
    Pharmacol Rev 57:117-45. 2005
    ..Molecular epidemiological techniques for monitoring parasite drug resistance may contribute to development of strategies for prolonging the useful therapeutic life of this important class of drugs...
  2. pmc Pneumocystis pneumonia in HIV-positive adults, Malawi
    Joep J G van Oosterhout
    University of Malawi College of Medicine, Blantyre, Malawi
    Emerg Infect Dis 13:325-8. 2007
    ..PcP incidence was highest in patients with the lowest CD4 counts, but PcP is uncommon compared with incidences of pulmonary tuberculosis and bacterial pneumonia...
  3. pmc Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    PLoS ONE 3:e1465. 2008
    ..The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria...
  4. pmc Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial
    Matthew B Laurens
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e79323. 2013
    ..Extended follow-up was conducted to evaluate extended safety, immunogenicity and efficacy...
  5. pmc Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial
    Mahamadou A Thera
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    PLoS ONE 5:e9041. 2010
    ..The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02(A) in children exposed to seasonal falciparum malaria...
  6. pmc Prevalence and distribution of human Plasmodium infection in Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:297. 2013
    ..This study was undertaken to determine the current prevalence and distribution of Plasmodium species across the country...
  7. pmc A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:300. 2013
    ..falciparum chloroquine resistance transporter (pfcrt), multidrug resistance (pfmdr1), dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes and the origin of chloroquine-resistant P. falciparum parasites...
  8. pmc Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan
    Aamer A Khattak
    Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 12:310. 2013
    ..The aims of this study were to determine the prevalence of polymorphisms in the SP resistance-associated genes pvdhfr, pvdhps and chloroquine resistance-associated gene pvmdr1 in P. vivax isolates collected from across the country...
  9. pmc Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali
    Drissa Coulibaly
    Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Point G, BP 1805, Bamako, Mali
    Malar J 12:82. 2013
    ..To assess time and space distribution of malaria disease in Bandiagara, Mali, within a transmission season, data were used from an ongoing malaria incidence study that enrolled 300 participants aged under six years old"...
  10. pmc Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment
    Ayesha M Shaukat
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 11:207. 2012
    ..The clinical benefit of preventing new infections has never been compared to that of curing the initial infection...
  11. pmc Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples
    Meera Venkatesan
    Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 11:41. 2012
    ..This study was undertaken to determine whether CF11 columns could be adapted to isolate Plasmodium falciparum DNA from parasitized whole blood and achieve current quantity and purity requirements for Illumina sequencing...
  12. pmc The rationale and plan for creating a World Antimalarial Resistance Network (WARN)
    Carol Hopkins Sibley
    Malar J 6:118. 2007
    ..WARN will serve as a public resource to guide antimalarial drug treatment and prevention policies and to help confirm and characterize the new emergence of new resistance to antimalarial drugs and to contain its spread...
  13. pmc World Antimalarial Resistance Network (WARN) IV: clinical pharmacology
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Malar J 6:122. 2007
    ....
  14. pmc World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
    Ric N Price
    International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Malar J 6:119. 2007
    ..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed...
  15. pmc A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa
    Shannon L Takala
    Center for Vaccine Development, University of Maryland School of Medicine, HSF1 480, Baltimore, Maryland 21201, USA
    Malar J 5:31. 2006
    ..Methods are needed to monitor genetic diversity in polymorphic vaccine antigens, but determining which genetic variants of such antigens are present in infected individuals is complicated by the frequent occurrence of mixed infections...
  16. pmc Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine
    Amed Ouattara
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, Mali
    Malar J 9:175. 2010
    ....
  17. pmc The evolution of drug-resistant malaria
    Christopher V Plowe
    Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Trans R Soc Trop Med Hyg 103:S11-4. 2009
    ....
  18. pmc World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria
    Christopher V Plowe
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, Maryland 21201, USA
    Malar J 6:121. 2007
    ....
  19. ncbi request reprint Antimalarial drug resistance in Africa: strategies for monitoring and deterrence
    C V Plowe
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, MA 21201, USA
    Curr Top Microbiol Immunol 295:55-79. 2005
    ..In the absence of an ideal antimalarial combination regimen, different treatment alternatives are appropriate in different settings. But where chloroquine has failed, policy changes are long overdue and action must be taken now...
  20. ncbi request reprint Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy
    C V Plowe
    Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA
    Am J Trop Med Hyg 64:242-6. 2001
    ..Modifications of the protocol for monitoring antimalarial therapeutic efficacy are recommended...
  21. ncbi request reprint Monitoring antimalarial drug resistance: making the most of the tools at hand
    Christopher V Plowe
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Exp Biol 206:3745-52. 2003
    ..This raises the intriguing possibility of rotating antimalarial drugs...
  22. pmc Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study
    Christopher V Plowe
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, MD 21044, USA
    BMJ 328:545. 2004
    ..To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993...
  23. ncbi request reprint Return of chloroquine antimalarial efficacy in Malawi
    Miriam K Laufer
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    N Engl J Med 355:1959-66. 2006
    ..The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi...
  24. ncbi request reprint Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America
    Joseph F Cortese
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 186:999-1006. 2002
    ..This study highlights the importance of continent-wide malaria-control policies and suggests that the containment of resistance to the next generation of therapies may be feasible...
  25. pmc Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali
    Shannon L Takala
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS Med 4:e93. 2007
    ....
  26. pmc Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods
    Shannon L Takala
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 76:855-9. 2007
    ....
  27. ncbi request reprint Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi
    James G Kublin
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:1870-5. 2003
    ..The reintroduction of chloroquine, ideally in combination with another antimalarial drug, should be considered in areas where chloroquine resistance has declined and safe and affordable alternatives remain unavailable...
  28. ncbi request reprint Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA
    J Infect Dis 193:872-8. 2006
    ..Human immunodeficiency virus (HIV) infection and malaria coexist in much of Africa. Previous studies differ in their findings on the interactions between the 2 infections...
  29. ncbi request reprint Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies
    Miriam K Laufer
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, HSF 1 480, Baltimore, MD 21201, USA
    Drug Resist Updat 7:279-88. 2004
    ..The finding that drug resistance decreases with the removal of drug pressure could provide a new paradigm for malaria treatment policies in Africa...
  30. ncbi request reprint Observational cohort study of HIV-infected African children
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Pediatr Infect Dis J 25:623-7. 2006
    ..Children identified through voluntary counseling and testing (VCT) represent a unique cohort that has not been previously described in the literature...
  31. pmc Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    J Infect Dis 202:801-8. 2010
    ..Chloroquine-susceptible parasites that predominate in Malawi likely represent a reexpansion of the susceptible parasites that survived in the population despite widespread drug pressure in the region...
  32. ncbi request reprint Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali
    Kirsten E Lyke
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF 480, Baltimore, MD, USA
    Vaccine 22:3169-74. 2004
    ..This approach may be useful in assessing the suitability of potential sites for malaria vaccine trials...
  33. pmc Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development
    Shannon L Takala
    Howard Hughes Medical Institute and Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Sci Transl Med 1:2ra5. 2009
    ..This extreme diversity may pose a serious obstacle to an effective polyvalent recombinant subunit apical membrane antigen-1 vaccine...
  34. ncbi request reprint Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria
    Kirsten E Lyke
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 69:253-9. 2003
    ....
  35. pmc Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial
    Kirsten E Lyke
    Center for Vaccine Development, University of Maryland, Baltimore, MD, United States
    Vaccine 27:2171-6. 2009
    ..These results provide evidence that complex immune responses can be induced by this vaccination strategy and add further impetus for the continuing clinical evaluation of this vaccine...
  36. ncbi request reprint Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria
    James G Kublin
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    J Infect Dis 185:380-8. 2002
    ..If this model is validated in other populations, it will finally be possible to use molecular markers for surveillance of antifolate-resistant P. falciparum malaria in Africa...
  37. ncbi request reprint Monitoring and deterring drug-resistant malaria in the era of combination therapy
    Miriam K Laufer
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    Am J Trop Med Hyg 77:160-9. 2007
    ..The malaria research and control community should not fail to exploit this opportunity to apply the lessons of the last 50 years to extend the useful therapeutic lives of ACTs...
  38. pmc Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial
    Kirsten E Lyke
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 5:e13490. 2010
    ..The standard model relies on the bite of five infected mosquitoes to induce malaria. We examined the efficacy of malaria transmission using mosquitoes raised aseptically in compliance with current Good Manufacturing Practices (cGMPs)...
  39. ncbi request reprint Malaria treatment efficacy among people living with HIV: the role of host and parasite factors
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 77:627-32. 2007
    ....
  40. pmc Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children
    Kirsten E Lyke
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 73:1124-30. 2005
    ..falciparum malaria was observed in children 9-14 years of age. We conclude that underlying schistosomiasis is associated with protection against clinical falciparum malaria in an age-dependent manner...
  41. pmc Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children
    Kirsten E Lyke
    Center for Vaccine Development, University of Maryland at Baltimore, 685 W Baltimore St, HSFI 480, Baltimore, MD 21201, USA
    Infect Immun 74:5718-24. 2006
    ..001) and the Sch(-) children (P < 0.001) who were 4 to 8 years old. We postulate that the Th2-enriched environment induced by schistosomiasis protects against malaria and alters the cytokine milieu during an actual infection...
  42. pmc HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls
    Kirsten E Lyke
    The University of Maryland at Baltimore, Center for Vaccine Development, 685 W Baltimore St, HSF 480, Baltimore, MD 21201, USA
    Infect Immun 73:5799-808. 2005
    ..However, whether these immune responses to TRAP, CSP, and Exp-1 malarial proteins play a substantial role in protection remains a matter of controversy...
  43. pmc Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia
    Helen M Kyriacou
    Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, UK
    Mol Biochem Parasitol 150:211-8. 2006
    ..These results suggest that var genes with DBLalpha1-like domains (Group A or B/A) may be implicated in the pathogenesis of cerebral malaria, while var genes with DBLalpha0-like domains promote less virulent malaria infections...
  44. ncbi request reprint Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?
    Miriam K Laufer
    Am J Trop Med Hyg 75:373-4. 2006
  45. ncbi request reprint Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones
    Abdoulaye A Djimde
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Dentistry, University of Bamako, Bamako, Mali
    J Infect Dis 190:853-5. 2004
    ..This example illustrates how molecular markers for drug resistance can provide timely data that inform malaria-control policy during epidemics and other emergency situations...
  46. ncbi request reprint A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria
    Dapa A Diallo
    faculté de médecine de pharmacie et d odontostomatologie, University of Bamako, Bamako, Mali
    Acta Trop 90:295-9. 2004
    ..By this measure, HbC, a malaria-protective polymorphism with few deleterious consequences, does not appear to be associated with more frequent anemia than normal HbA in episodes of uncomplicated P. falciparum malaria...
  47. ncbi request reprint Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria
    Abdoulaye A Djimde
    Bandiagara Malaria Project, Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako, Mali
    Am J Trop Med Hyg 69:558-63. 2003
    ..Age-adjusted comparison of subjects able to clear resistant parasites and those unable to do so provides a new phenotype for identifying host immune and genetic factors responsible for protective immunity against malaria...
  48. ncbi request reprint Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali
    Drissa Coulibaly
    Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Mali, Bamako, Mali, West Africa
    Am J Trop Med Hyg 67:604-10. 2002
    ....
  49. ncbi request reprint Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar
    Carmen E Contreras
    Immunology Institute, School of Medicine, Central University, Caracas, Venezuela
    Am J Trop Med Hyg 67:400-5. 2002
    ..falciparum malaria in Bolivar, and an invasion of multi-resistant pathogens from Brazil. Despite national restrictions on the use of SP and chloroquine, genotypic resistance to these therapies remains widespread in Bolivar...
  50. ncbi request reprint Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria
    Fabian Mendez
    Secretaría Departamental de Salud del Valle, Cali, Colombia
    Am J Epidemiol 156:230-8. 2002
    ..These results suggest that even when SP efficacy is high, DHFR mutations that are insufficient to cause therapeutic failure may nevertheless increase malaria transmission and promote the spread of drug resistance...
  51. pmc Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls
    Yacouba Cissoko
    Bandiagara Malaria Project, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Malaria Research and Training Center, University of Bamako, Bamako, Mali
    Am J Trop Med Hyg 75:199-204. 2006
    ..A direct correlation between age and parasitemia and IgG antibodies to GPI was observed. In summary, higher levels of IgM and IgG antibodies to GPI in young children were associated with disease severity and were short-lived...
  52. pmc Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence
    Anne Marie Deans
    Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
    Am J Trop Med Hyg 74:554-63. 2006
    ..This raises the possibility of differences in the mechanisms of malaria virulence between sub-Saharan Africa and Asia...
  53. ncbi request reprint Community permission for medical research in developing countries
    Dapa A Diallo
    Department of Hematology, Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Mali
    Clin Infect Dis 41:255-9. 2005
    ..Far from competing with the individual informed consent process, the process of obtaining community permission both initiated and facilitated the process of disclosure for individual informed consent...
  54. pmc Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease
    Mahamadou A Thera
    Bandiagara Malaria Project, Malaria Research and Training Center, University of Bamako, Mali
    J Infect Dis 192:1823-9. 2005
    ..CONCLUSIONS. In this setting of low antifolate resistance, TS was highly effective in preventing falciparum malaria infection and disease and did not appear to select for SP-resistant parasites...
  55. ncbi request reprint Use of area under the curve to characterize transmission potential after antimalarial treatment
    Fabian Mendez
    Escuela de Salud Publica, Universidad del Valle, Cali, Colombia
    Am J Trop Med Hyg 75:640-4. 2006
    ..Methods presented are applicable to both observational studies and clinical trials assessing the effect of therapies on transmission potential...
  56. ncbi request reprint Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria
    Fraction K Dzinjalamala
    Division of Pharmacology, University of Cape Town, Cape Town, South Africa
    Am J Trop Med Hyg 72:267-72. 2005
    ....
  57. ncbi request reprint Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes
    Fabian Mendez
    Escuela de Salud Publica, Universidad del Valle, Cali, Colombia
    Am J Trop Med Hyg 77:438-43. 2007
    ..23, P < 0.05). Low-level drug resistance mutations have the potential to enhance transmission of P. falciparum and spread resistant parasites...
  58. ncbi request reprint A network to monitor antimalarial drug resistance: a plan for moving forward
    Carol Hopkins Sibley
    Department of Genome Sciences, University of Washington, Seattle, WA, USA
    Trends Parasitol 24:43-8. 2008
    ....
  59. pmc Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children
    Monica Arman
    Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
    Am J Trop Med Hyg 77:943-6. 2007
    ..001) but not with disease category (F(2,122) = 1.8, P = 0.17). Therefore platelet-mediated clumping in Malian P. falciparum isolates is primarily associated with high parasitemia and not with severe clinical manifestations of malaria...
  60. pmc Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children
    Fraction K Dzinjalamala
    University of Cape Town, Division of Clinical Pharmacology, K50 Old Main Building, Groote Schuur Hospital, Cape Town 7925, South Africa
    Antimicrob Agents Chemother 49:3601-6. 2005
    ..falciparum should be interpreted with caution and needs further validation...
  61. ncbi request reprint Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
    D Gray Heppner
    Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Vaccine 23:2243-50. 2005
    ..Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine...
  62. pmc Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi
    David J Bell
    Department of Molecular and Biochemical Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
    PLoS ONE 3:e1578. 2008
    ..Here we compare the efficacy, safety and selection of resistance using SP or CQ+SP or artesunate (ART)+SP or AQ+SP for the treatment of uncomplicated falciparum malaria...
  63. ncbi request reprint Combination therapy for malaria: mission accomplished?
    Christopher V Plowe
    Clin Infect Dis 44:1075-7. 2007
  64. pmc Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting
    J Alexandra Rowe
    Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, United Kingdom
    Proc Natl Acad Sci U S A 104:17471-6. 2007
    ..falciparum rosetting. This work provides insights into malaria pathogenesis and suggests that the selective pressure imposed by malaria may contribute to the variable global distribution of ABO blood groups in the human population...
  65. ncbi request reprint A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV
    Joep J G van Oosterhout
    Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    J Acquir Immune Defic Syndr 39:626-31. 2005
    ..These should also assess benefit in patients receiving antiretroviral therapy...

Research Grants12

  1. DRUG RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 1999
    ..abstract_text> ..
  2. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2007
    ..These studies are expected to add to our knowledge of the molecular basis of antifolate-resistant malaria and to provide information of direct and immediate relevance to HIV and malaria control policies in Africa. ..
  3. Clinical trial of chloroquine combinations in Malawi
    CHRISTOPHER PLOWE; Fiscal Year: 2007
    ..Results of the proposed studies will also inform malaria treatment policies in other countries where chloroquine is still used or has recently been discontinued. ..
  4. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2003
    ....
  5. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2002
    ....
  6. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2002
    ..abstract_text> ..
  7. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2001
    ..abstract_text> ..
  8. TS PROPHYLAXIS AND DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2001
    ....
  9. DRUG-RESISTANT MALARIA IN MALAWI
    CHRISTOPHER PLOWE; Fiscal Year: 2000
    ..abstract_text> ..